This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamilton, J. A. Articles by Watts, C. K. W. Search for Related Content PubMed PubMed Citation Articles by Hamilton, J. A. Articles by Watts, C. K. W.

Identification of PRG1, A Novel Progestin-Responsive Gene with Sequence Homology to 6-Phosphofructo-2-Kinase/Fructose- 2,6-Bisphosphatase

Cancer Research Program Garvan Institute of Medical Research St. Vincent’s Hospital Sydney, New South Wales 2010, Australia

To define early molecular targets of progestin action, the differential display technique was used to identify genes with altered levels of expression in T-47D breast cancer cells treated with the synthetic progestin ORG 2058 for 3 h. PRG1 was first isolated as a 200-bp cDNA clone and its progestin regulation confirmed by Northern analysis. Cloning of the complete coding region of PRG1 revealed that it shared a high degree of amino acid sequence identity with isoforms of the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase from several tissues and species. Expression of PRG1 mRNA was observed in several normal breast epithelial and breast cancer cell lines and in a variety of human tissues, with highest expression in the breast, aorta, and brain. In T-47D cells, PRG1 mRNA was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h. Progestin-induced increases in PRG1 mRNA were inhibited by the progestin antagonist RU 486 and occurred via the progesterone receptor. Progestin induction of PRG1 mRNA was also inhibited by actinomycin D but not by cycloheximide. PRG1 is therefore a novel human gene that is directly regulated by progestins via the progesterone receptor.

This article has been cited by other articles:

				A. Yalcin, B. F. Clem, A. Simmons, A. Lane, K. Nelson, A. L. Clem, E. Brock, D. Siow, B. Wattenberg, S. Telang, et al. Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases J. Biol. Chem., September 4, 2009; 284(36): 24223 - 24232. [Abstract] [Full Text] [PDF]

				R. J. Gillies, I. Robey, and R. A. Gatenby Causes and Consequences of Increased Glucose Metabolism of Cancers J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S. [Abstract] [Full Text] [PDF]

				B. Clem, S. Telang, A. Clem, A. Yalcin, J. Meier, A. Simmons, M. A. Rasku, S. Arumugam, W. L. Dean, J. Eaton, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol. Cancer Ther., January 1, 2008; 7(1): 110 - 120. [Abstract] [Full Text] [PDF]

				M. Obach, A. Navarro-Sabate, J. Caro, X. Kong, J. Duran, M. Gomez, J. C. Perales, F. Ventura, J. L. Rosa, and R. Bartrons 6-Phosphofructo-2-kinase (pfkfb3) Gene Promoter Contains Hypoxia-inducible Factor-1 Binding Sites Necessary for Transactivation in Response to Hypoxia J. Biol. Chem., December 17, 2004; 279(51): 53562 - 53570. [Abstract] [Full Text] [PDF]

				T. Atsumi, J. Chesney, C. Metz, L. Leng, S. Donnelly, Z. Makita, R. Mitchell, and R. Bucala High Expression of Inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (iPFK-2; PFKFB3) in Human Cancers Cancer Res., October 15, 2002; 62(20): 5881 - 5887. [Abstract] [Full Text] [PDF]

				J. X. Perez, T. Roig, A. Manzano, M. Dalmau, J. Boada, F. Ventura, J. L. Rosa, J. Bermudez, and R. Bartrons Overexpression of fructose 2,6-bisphosphatase decreases glycolysis and delays cell cycle progression Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1359 - C1365. [Abstract] [Full Text] [PDF]